Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332.


Journal

Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Titre abrégé: J Enzyme Inhib Med Chem
Pays: England
ID NLM: 101150203

Informations de publication

Date de publication:
Dec 2021
Historique:
entrez: 22 7 2021
pubmed: 23 7 2021
medline: 27 7 2021
Statut: ppublish

Résumé

The chemical structure of PF-07321332, the first orally available Covid-19 clinical candidate, has recently been revealed by Pfizer. No information has been provided about the interaction pattern between PF-07321332 and its biomolecular counterpart, the SARS-CoV-2 main protease (M

Identifiants

pubmed: 34289752
doi: 10.1080/14756366.2021.1954919
pmc: PMC8300928
doi:

Substances chimiques

Antiviral Agents 0
Lactams 0
Ligands 0
Nitriles 0
Protease Inhibitors 0
nirmatrelvir 7R9A5P7H32
Proline 9DLQ4CIU6V
Peptide Hydrolases EC 3.4.-
Leucine GMW67QNF9C

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1646-1650

Références

Am J Clin Pathol. 2020 Mar 9;153(4):420-421
pubmed: 32053148
J Chem Inf Model. 2009 Jan;49(1):84-96
pubmed: 19125657
Bioinformatics. 2011 Jun 1;27(11):1575-7
pubmed: 21471012
Nat Commun. 2021 Jan 12;12(1):279
pubmed: 33436624
Nature. 2020 Jun;582(7811):289-293
pubmed: 32272481
ACS Comb Sci. 2020 Jun 8;22(6):297-305
pubmed: 32402186
Biophys J. 2010 Apr 7;98(7):1327-36
pubmed: 20371333
J Med Virol. 2020 May;92(5):479-490
pubmed: 32052466
Expert Opin Ther Pat. 2021 Apr;31(4):309-324
pubmed: 33246378
Acc Chem Res. 2008 Jan;41(1):50-9
pubmed: 18193821
J Chem Theory Comput. 2009 Jun 9;5(6):1632-9
pubmed: 26609855
PLoS Comput Biol. 2017 Jul 26;13(7):e1005659
pubmed: 28746339
Rev Panam Salud Publica. 2020 Mar 20;44:e40
pubmed: 32256547
J Chem Inf Model. 2014 Feb 24;54(2):372-6
pubmed: 24456045
ChemMedChem. 2021 Jul 6;16(13):2075-2081
pubmed: 33797868
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Sci Rep. 2021 Apr 1;11(1):7429
pubmed: 33795718
Lancet. 2020 Feb 22;395(10224):542-545
pubmed: 32061313
Sci Rep. 2020 Dec 1;10(1):20927
pubmed: 33262359

Auteurs

Matteo Pavan (M)

Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.

Giovanni Bolcato (G)

Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.

Davide Bassani (D)

Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.

Mattia Sturlese (M)

Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.

Stefano Moro (S)

Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH